Navigation Links
University of Minnesota startup to treat challenging bacterial infection
Date:5/16/2012

A live biological preparation developed by University of Minnesota researchers could put a stop to an increasingly prevalent, and sometimes deadly, infection caused by the bacterium Clostridium difficile. CIPAC Limited, based in Australia with subsidiaries in California, will continue to work with the university to advance the technology to treat patients by using frozen and, eventually, encapsulated preparations.

C. difficile affects several million people and is linked to 14,000 deaths per year in the United States, according to the Centers for Disease Control and Prevention. Symptoms of C. difficile infection include fever, nausea, and diarrhea, and most often occur following a prescribed course of antibiotics. The antibiotics kill normal microbes that live in the colon, thereby making the patient more susceptible to infections such as C. difficile.

Paradoxically, while the cause of C. difficile infection is exposure to antibiotics, the infection itself is also treated using antibiotics, which can make things worse. C. difficile infections typically affect older adults in hospitals or in long-term care facilities, but is increasingly spreading into the wider community. In recent years it has become more frequent, more severe and more difficult to treat. Patients suffering from the infection require costly care -- researchers suggest it costs $2,500-7,000 to treat each patient suffering from C. difficile.(1)

"C. difficile can be suppressed with antibiotics, which have the unfortunate side effect of killing off the normal colon bacteria that offer protection against infection," says Alexander Khoruts, M.D., co-inventor and associate professor of medicine within the university's division of Gastroenterology, Hepatology and Nutrition.

"Antibiotics don't work very well because they only suppress the C. difficile. Once you remove the antibiotic, it produces more of the infection," says Michael Sadowsky, co-inventor and McKnight University professor in the Biotechnology Institute and department of Soil, Water, and Climate.

The invention, a bacterial preparation, can enable restoration of normal bacteria in the colon.

"We are very excited to be working with the University of Minnesota in commercializing a treatment that has approximately 95% efficacy," says Geoff Rosenhain, founder of CIPAC. "Our goal is to bring to market a safe, natural and effective alternative to current treatment options, and to restore the wellbeing of patients suffering from debilitating C. difficile infections."

CIPAC is working with the FDA to begin clinical trials for the preparation. The technology was licensed exclusively to CIPAC by the university's Office for Technology Commercialization.


'/>"/>

Contact: John Merritt
jmerritt@umn.edu
612-624-2609
University of Minnesota
Source:Eurekalert

Related medicine news :

1. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
2. University of Houston Graduate College of Social Work announces partnership with MD Anderson
3. Neuropsychologist receives University of Houstons highest faculty honor
4. Louisiana Tech University professor earns NSF Early Career Development grant
5. Rice University student engineers automate limb lengthening for kids
6. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
7. University of Cincinnati researchers win $3.7M grant from US Department of Defense
8. Oxford University Press partners with the Physical Society of Japan
9. Fewer women need repeat breast cancer surgeries with new service at University of Michigan
10. Kessler Foundation scientist addresses opening of science complex of William Paterson University
11. 90 percent of firefighters exhibit symptoms of PTSD according to Ben-Gurion University researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2020)... LAUREL, N.J. (PRWEB) , ... May 27, 2020 ... ... contract manufacturer, announces that it is now manufacturing face shields to be ... novel coronavirus that causes COVID-19. These face shields are single use, made to ...
(Date:5/27/2020)... ... May 27, 2020 , ... ... of Washington Professor of Bioengineering, Founder & Editor of scientific journal WATER, ... ( https://www.amazon.com/Fourth-Phase-Water-Beyond-Liquid-ebook/dp/B00N2ASKF2 ) , https://www.voiceamerica.com/episode/123059/the-fourth-phase-of-water , * , During ...
(Date:5/26/2020)... ... , ... Today TRC Companies (“ TRC ”) announced the release of its ... owners and leaders assess whether their organizations are prepared to move forward as the ... intended to assist business leaders evaluate their readiness relative to CDC guidance and provides ...
(Date:5/25/2020)... ... ... Winemaker Grant Long Jr. is introducing three Toilet Paper Reserve wines. “These are ... complicated times,” he said, in announcing the new wines. The wines are 2019 Chardonnay ... Wine Blend are sourced in the Napa Valley; the Grenache comes from the El ...
(Date:5/21/2020)... Minn. (PRWEB) , ... May 21, 2020 , ... ... medical device manufacturer, announces its first milestone to deliver over one million FDA-compliant ... eight weeks. Summit Medical Face Shields meet the critical need for personal protective ...
Breaking Medicine News(10 mins):
(Date:5/21/2020)... ... May 21, 2020 , ... ... needs in the field of urology, today announced that Naveen Divakaruni, D.O., Advocate ... Excellence. The designation recognizes that Dr. Divakaruni has achieved a high level of ...
(Date:5/21/2020)... ... ... Labyrinthe Labs has announced the launch of its brand new and ground-breaking ... for fast-action relief of joint and muscle soreness, Lefa is botanically powered by a ... and muscles. , According to the National Institutes of Health , approximately ...
(Date:5/17/2020)... ... 2020 , ... The Sea Cucumber-derived triterpenoid glycoside Frondoside A, which has been ... the Sea Cucumber in a proprietary process to give SeaCare Dietary Supplement ... and time again: “You get what you pay for.” It is usually in reference ...
Breaking Medicine Technology: